These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22673025)

  • 1. The growing importance of PON1 in cardiovascular health: a review.
    Macharia M; Hassan MS; Blackhurst D; Erasmus RT; Matsha TE
    J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):443-53. PubMed ID: 22673025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine.
    van Himbergen TM; van Tits LJ; Roest M; Stalenhoef AF
    Neth J Med; 2006 Feb; 64(2):34-8. PubMed ID: 16517986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of genetic (PON1 polymorphism) and environmental factors, especially physical activity, in antioxidant function of paraoxonase.
    Otocka-Kmiecik A; Orłowska-Majdak M
    Postepy Hig Med Dosw (Online); 2009 Dec; 63():668-77. PubMed ID: 20097953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite.
    Connelly PW; Draganov D; Maguire GF
    Free Radic Biol Med; 2005 Jan; 38(2):164-74. PubMed ID: 15607900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Paraoxonase: its multiple functions and pharmacological regulation].
    Fridman O; Fuchs AG; Porcile R; Morales AV; Gariglio LO
    Arch Cardiol Mex; 2011; 81(3):251-60. PubMed ID: 21975240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of paraoxonases: a brief review.
    Draganov DI; La Du BN
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):78-88. PubMed ID: 14579013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of paraoxonase 1 (PON1) in organophosphate metabolism: implications in neurodegenerative diseases.
    Androutsopoulos VP; Kanavouras K; Tsatsakis AM
    Toxicol Appl Pharmacol; 2011 Nov; 256(3):418-24. PubMed ID: 21864557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The paraoxonase gene family and atherosclerosis.
    Ng CJ; Shih DM; Hama SY; Villa N; Navab M; Reddy ST
    Free Radic Biol Med; 2005 Jan; 38(2):153-63. PubMed ID: 15607899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paraoxonases role in the prevention of cardiovascular diseases.
    Rosenblat M; Aviram M
    Biofactors; 2009; 35(1):98-104. PubMed ID: 19319852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in paraoxonase-1 activity and atherosclerosis.
    Soran H; Younis NN; Charlton-Menys V; Durrington P
    Curr Opin Lipidol; 2009 Aug; 20(4):265-74. PubMed ID: 19550323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1.
    Deakin SP; James RW
    Clin Sci (Lond); 2004 Nov; 107(5):435-47. PubMed ID: 15265000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylmercury-induced inhibition of paraoxonase-1 (PON1)-implications for cardiovascular risk.
    Ginsberg G; Sonawane B; Nath R; Lewandowski P
    J Toxicol Environ Health A; 2014; 77(17):1004-23. PubMed ID: 25072822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraoxonase and atherosclerosis-related cardiovascular diseases.
    Chistiakov DA; Melnichenko AA; Orekhov AN; Bobryshev YV
    Biochimie; 2017 Jan; 132():19-27. PubMed ID: 27771368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The paraoxonases: role in human diseases and methodological difficulties in measurement.
    Camps J; Marsillach J; Joven J
    Crit Rev Clin Lab Sci; 2009; 46(2):83-106. PubMed ID: 19255916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.
    Kim DS; Marsillach J; Furlong CE; Jarvik GP
    Pharmacogenomics; 2013 Sep; 14(12):1495-515. PubMed ID: 24024900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans.
    Lacinski M; Skorupski W; Cieslinski A; Sokolowska J; Trzeciak WH; Jakubowski H
    Cell Mol Biol (Noisy-le-grand); 2004 Dec; 50(8):885-93. PubMed ID: 15704252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of paraoxonase (PON1) activity.
    Costa LG; Vitalone A; Cole TB; Furlong CE
    Biochem Pharmacol; 2005 Feb; 69(4):541-50. PubMed ID: 15670573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A long and winding road: defining the biological role and clinical importance of paraoxonases.
    James RW
    Clin Chem Lab Med; 2006; 44(9):1052-9. PubMed ID: 16958594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity.
    James RW; Deakin SP
    Free Radic Biol Med; 2004 Dec; 37(12):1986-94. PubMed ID: 15544917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Concerning the significance of paraoxonase-1 and SR-B1 genes in atherosclerosis].
    Rodríguez Esparragón F; Hernández Trujillo Y; Macías Reyes A; Hernández Ortega E; Medina A; Rodríguez Pérez JC
    Rev Esp Cardiol; 2006 Feb; 59(2):154-64. PubMed ID: 16540037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.